These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34481124)

  • 1. Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes.
    Yu J; Du Y; Jalil A; Ahmed Z; Mori S; Patel R; Varela JC; Chang CC
    Leuk Res; 2021 Nov; 110():106701. PubMed ID: 34481124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct Mutation Landscapes Between Acute Myeloid Leukemia With Myelodysplasia-Related Changes and De Novo Acute Myeloid Leukemia.
    Gao Y; Jia M; Mao Y; Cai H; Jiang X; Cao X; Zhou D; Li J
    Am J Clin Pathol; 2022 May; 157(5):691-700. PubMed ID: 34664628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes.
    Badar T; Szabo A; Sallman D; Komrojki R; Lancet J; Padron E; Song J; Hussaini MO
    Leuk Lymphoma; 2020 Jun; 61(6):1418-1427. PubMed ID: 32013644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
    Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
    Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes.
    Yokoyama K; Shimizu E; Yokoyama N; Nakamura S; Kasajima R; Ogawa M; Takei T; Ito M; Kobayashi A; Yamaguchi R; Imoto S; Miyano S; Tojo A
    Blood Adv; 2018 Oct; 2(19):2513-2521. PubMed ID: 30282643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome.
    Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Guo R; Tierens A; Minden MD; Chang H
    Hum Pathol; 2020 Oct; 104():117-126. PubMed ID: 32798550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
    Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
    Weinberg OK; Seetharam M; Ren L; Seo K; Ma L; Merker JD; Gotlib J; Zehnder JL; Arber DA
    Blood; 2009 Feb; 113(9):1906-8. PubMed ID: 19131546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
    Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
    Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical and prognostic characteristics of pediatric acute myeloid leukemia with myelodysplasia-related changes under different diagnostic criteria].
    Zhang RR; Ruan M; Liu TF; Wang SC; Zhang XY; Qi BQ; Zhu XF; Zhang L
    Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):250-255. PubMed ID: 38378287
    [No Abstract]   [Full Text] [Related]  

  • 15. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
    He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
    Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
    Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns.
    Guan W; Zhou L; Li Y; Yang E; Liu Y; Lv N; Fu L; Ding Y; Wang N; Fang N; Liu Q; Wang B; Li F; Zhang J; Wang M; Wang L; Jing Y; Li Y; Yu L
    Exp Hematol Oncol; 2021 Apr; 10(1):27. PubMed ID: 33836835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
    Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
    Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.